Camurus AB (CAMRF) reports a 52% revenue increase, strategic licensing with Eli Lilly, and EU approval of Oczyesa, despite currency challenges and market hurdles.

"Successful second quarter for Camurus" Summary second quarter 2025 April - June Total revenues grew 52% (65% at CER1) to SEK 676 (445) million Sales of Buvidal® increased 17% (26% at CER1) to SEK ...

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal ® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Lund, Sweden - 14 May 2025 - Camurus (NASDAQ STO: CAMX) today announced that Anders Vadsholt has been appointed as Camurus' Chief Financial Officer (CFO) and member of the executive management team, ...

Most adults with acromegaly reduced IGF-1 levels and improved acromegaly symptoms with once-monthly subcutaneous octreotide ...

Camurus (OTC:CAMRF) is a biopharmaceutical company that develops and commercializes medicines for severe and chronic diseases globally. While Eli Lilly and Company (NYSE:LLY) discovers, develops ...

New PDUFA action date for Brixadi set for 15 December 2021 LUND, Sweden, June 26, 2021 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) announced today that the New Drug Application (NDA) by Camurus' US ...

We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring ...

Camurus AB Fredrik Tiberg, President & CEO Tel. +46 (0)46 286 46 92 [email protected] Fredrik Joabsson, Chief Business Development Officer Tel. +46 (0)70 776 17 37 [email protected] Site Navigation ...

LUND, Sweden, June 4, 2019 /PRNewswire/ -- Camurus announces that the leading drug dependence journal Addiction has today published full results from a 48-week, open-label, global Phase 3 study of ...